Skip to content
Back to news

Servier India: A milestone achievement in the fight against cancers

With an estimated 14.6 million cases of cancer in 20221, India is facing a major challenge. In fact, one person in nine is likely to develop cancer during his or her lifetime 1.

Considering India’s population size and the increasing burden of pancreatic cancer, the introduction of a new medicine for pancreatic cancer patients marks a major milestone.

Pancreatic cancer is one of the cancer types with the poorest prognosis, given a five-year survival rate of just 11%2. Diagnosis is most often made at an advanced stage, when the tumor is no longer operable due to the disease’s late clinical expression. 

According to the World Health Organization, cancer is the second leading cause of death worldwide3 and is steadily on the rise. To address the growing need for therapeutic solutions, we have made oncology one of our priority innovation areas.

Launching this treatment in India is directly aligned with our Servier 2030 ambition of being a leading and innovative player in the treatment of rare cancers. Our major commitment to the battle against rare cancers is currently reflected in 9 treatments now available to patients worldwide and more than 70% of our R&D budget allocated to oncology.

00:00 / 00:00

 
1 https://pubmed.ncbi.nlm.nih.gov/36510887/#:~:text=The%20age%2Dspecific%20incidence%20rate,rate%3A100.4%20per%20100%2C000).
2 – Source: American Cancer Society. Cancer Facts & Figures 2023. Atlanta: American Cancer Society; 2022.
3 – World Health Organization – https://www.who.int/fr/health-topics/cancer#:~:text=Le%20terme%20cancer%20est%20%C3%A9galement%20connu%20sous%20le,morts%20en%202018%2C%20soit%20un%20d%C3%A9c%C3%A8s%20sur%20six.